The prevalence of MASLD and MASH are growing. As Nadege Gunn, MD, CPI, says, “Clinical research is really the opportunity we have to give our patients some hope and some perspective that their disease will one day soon be treatable.” As leaders of the Velocity MASH CARE Council, Dr. Gunn and Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, advise more than 20 sites conducting MASH clinical trials. As Dr. Kowdley explains, “[CARE Councils can] transfer the information and knowledge that someone like myself has accumulated over 30 years of doing research to sites that are capable, interested, and have the patient population.” Learn more about Velocity's MASH CARE Council: https://lnkd.in/g57vYKCf #CARECouncils #MASH #MASLD #Liver #Hepatology #Metabolic
Velocity Clinical Research, Inc.
Biotechnology Research
Durham, North Carolina 22,330 followers
Delivering high-quality clinical trial data and patient care with unprecedented efficiency.
About us
Velocity is the world’s leading organization of fully integrated clinical research sites. With 90 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing. Velocity offers unified research site solutions to efficiently provide the right patients, investigators, and research staff for clinical trials across the U.S. and Europe. The company also operates a technology hub in India, where it is unlocking a new era in clinical research by developing innovative systems to leverage expansive site, patient, and historical performance data. To learn more about how Velocity delivers high-quality data, exemplary patient care, and unprecedented efficiency for clinical trials at any scale, visit VelocityClinical.com.
- Website
-
https://velocityclinical.com
External link for Velocity Clinical Research, Inc.
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Durham, North Carolina
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Clinical trials, Patient Recruitment, Vaccine Research, Pharmaceutical Research, Clinical Research, Vaccines, Neurology, Pediatrics, NASH, Infectious Disease, Dermatology, Women's Health, Gastroenterology, Alllergy, Medical Devices, Research Sites, Principal Investigators, and Drug Development
Locations
Employees at Velocity Clinical Research, Inc.
Updates
-
Rick Fisher, Senior VP, Operations, is returning to the ACRP - Association of Clinical Research Professionals #Ride4DEI next month. Starting in 2021, Rick and Sergio Armani teamed up to complete this grueling journey through mountains and mud, venturing from Pittsburgh, PA, to Washington D.C., to raise funds to improve diversity and inclusion in the clinical research workforce. Over the past few years, the number of cyclists and the amounts raised have grown, providing ACRP educational scholarships — including attendance at the ACRP’s annual conference — for entry-level clinical research professionals from diverse communities. Consider joining Velocity in supporting this great initiative. Donate: https://lnkd.in/gaybZfRT
-
About a year after Lacanemab was approved by the FDA for the treatment of Alzheimer’s, we spoke with Robert Cupelo, MD, Principal Investigator at Velocity’s Syracuse, NY site about the drug’s impact and the future of Alzheimer’s disease treatment. “Just like leukemia and AIDS, the treatment for Alzheimer's is going to be a combination, a cocktail,” he muses. “Maybe one drug to get rid of the amyloid, plus an anti-inflammatory, or one of these medicines that block the enzyme so you can't make the amyloid anymore. That's the way we conquered AIDS, combinations that support each other.” Hear more from Dr. Cupelo: https://lnkd.in/gnjpVb_C #AlzheimersDisease #ClinicalResearch #CNS
-
ERS Congress 2024 is a month away! If you’ll be in #Vienna, be sure to attend the C2 Industry Lunchtime Symposium on Monday, September 9 at 12:15 p.m. to see Henrik Watz, Medical Director and Principal Investigator for Velocity in Grosshansdorf, Germany. Dr. Watz will introduce a Sanofi Regeneron symposium, “A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation.”
-
We're excited to announce that Rachael Buck, Ph.D, is joining Velocity to lead our operations in the United Kingdom. With extensive experience in driving the growth of numerous sites and partnerships, Dr. Buck brings a wealth of expertise to our U.K. team. She previously oversaw global quality assurance, project management, the EMEA medical team, and project technology operations as a senior director of site networks at Accellacare. Rachael's leadership experience across numerous regions and therapeutic areas, as well as her focus on patient-centric site operations, will help continue to expand Velocity's presence and capabilities in the U.K. Please join us in welcoming Rachael to the team! Read the full press release, shared by The Associated Press: https://lnkd.in/gDDX3Rfz
-
Congratulations to Nadege Gunn, MD, CPI! Dr. Gunn is a finalist for the Healio Health Equity Award, which goes to a physician who has driven meaningful change to overcome the social determinants of health in gastroenterology, thereby improving patient care. As a leader of Velocity's MASH CARE Council, Dr. Gunn is advising how more than 20 sites that support liver disease trials engage patients and conduct NASH studies. Vote for Dr. Gunn at https://lnkd.in/eB8kffde You can also read a 2023 Q&A with Dr. Gunn, in which she discusses Black representation in liver disease clinical trials and variance in MASH diagnoses and care for the Black community: https://lnkd.in/gbgkgDtA #CARECouncils #MASH #ClinicalTrials
🥼 #HealthEquity has always been an Olympic sport to these nominees but who will take home the 🏅at our celebration in October? 🗳️Vote here: https://lnkd.in/eB8kffde Nadege Gunn, MD, CPI Rachel Issaka, MD, MAS MD Edwin K. McDonald IV, MD, University of Chicago Neilanjan Nandi, MD, FACP, AGAF, FACP Kira Newman, MD Christopher Vélez, MD, Massachusetts General Hospital
-
Thanks to science, vaccines have helped us fight many potentially fatal or debilitating diseases. This #NationalImmunizationAwarenessMonth, we encourage everyone to learn more about the vaccines available to them, and to consider joining a clinical trial to support the next generation of live-saving vaccines. Learn more at buff.ly/3qtsXed. #NIAM #PowerToProtect #vaccines #clinicalresearch
-
Jennifer Carl introduces this edition of The Recap, spotlighting our Growth & Development team's impact and exploring how Velocity continues to scale up while maintaining the agility needed to support trials of all sizes. Topics include: • A milestone in improving patient stipend payments • Continued expansion in the U.S. and across Europe Subscribe to The Recap here on LinkedIn or at https://lnkd.in/grZdGsK4
The Recap: August 2024
Velocity Clinical Research, Inc. on LinkedIn
-
Last week, at the request of the U.S. Department of State and the Cleveland Council on World Affairs, our Cleveland site hosted scientists and researchers from Kazakhstan to share our perspectives and experiences in conducting clinical trials. Principal Investigators Gerald Cephas, M.D., and Margaret Rhee, MD, gave our guests a tour of the facility and answered questions. Thank you, Drs. Cephas and Rhee, for sharing your decades of research experience!
-
This is why we do what we do. Velocity sites and investigators have supported research for nine products that have received U.S. FDA approval in 2024. These include: • Madrigal Pharmaceuticals' Rezdiffra (resmetirom), the first FDA-approved #MASH drug. • Moderna's mRESVIA, an mRNA RSV vaccine for adults 60 and older. • Eli Lilly and Company's Kisunla (donanemab) for patients with early symptomatic Alzheimer's. • Ipsen's Iquirvo, the first primary biliary cholangitis treatment approved by the FDA in over a decade, with significant contributions from our own Kris Kowdley, MD, the primary investigator for the Phase 3 trial. • Pfizer’s Penbraya, a meningococcal vaccine for people aged 10 to 25. To date, Velocity sites and investigators have contributed to research for over 60 product approvals, including more than 20 since 2023. Once again, we're grateful to our patients, employees, clients, and partners who make this progress possible. The journey continues… #ClinicalTrials #ClinicalResearch #CARECouncils